The institute’s new focus emphasizes scientific rigor and establishment of global standards for longevity clinics, enhancing credibility.
The International Institute of Longevity (IIOL), initially founded in 2018 by Joanna Bensz and Prince Michael of Liechtenstein, has announced a significant strategic relaunch in 2024 with Tina Woods joining as its new Executive Director. Accompanying this shift is an advisory board led by Dr Eric Verdin, comprising other leading experts in the field of longevity science. This renewed direction is aimed at fostering global standards and best practices in the application of longevity science, particularly within clinical and corporate wellness contexts.
In light of this revitalized focus, the IIOL’s role as a think tank is expanding into a comprehensive platform for professional practice – one that prioritizes policy advocacy and collaboration with wellness industries. The institute is committed to bridging scientific knowledge and real-world application, integrating advancements in personalized medicine, genomics, and AI into practical longevity solutions for healthcare providers and consumers alike. By advocating for decentralized human trials, IIOL seeks to accelerate innovation through data-sharing and the refinement of therapeutic approaches, ultimately driving the industry towards better quality and consumer protection.
Longevity.Technology: The relaunch arrives at a key time for the longevity sector; consumer interest in health and wellness is surging, coupled with a sharp increase in investor engagement in areas ranging from biotech to longevity-oriented services. This trend mirrors a broader shift in priorities post-pandemic, with health optimization, prevention and lifestyle interventions rightly assuming a more central role in addressing chronic disease and promoting resilience. However, the rapid influx of businesses and services touting ‘longevity benefits’ also raises concerns about the lack of regulatory oversight, which can expose the industry to risks of malpractice and diminish public trust. As such, the institute’s mission to advocate for a need for evidence-based, scientifically validated approaches in a field often plagued by unsubstantiated claims is a timely one.
Promoting a unified approach to longevity science
The IIOL recognizes that the complexity of aging, a process shaped by genetic, environmental and lifestyle factors, demands an integrated approach. As the longevity industry increasingly embraces novel therapeutic interventions, including lifestyle changes and targeted drugs, the institute is positioned to lead in setting clinical standards that guide these developments. New Executive Director Tina Woods explains: “The International Institute on Longevity serves an emerging need to develop and spread best practice and expertise, through a shared language backed up by standards, protocols and guidelines, to guide the growing number of longevity clinics worldwide while protecting consumers and minimizing reputational risk to the sector.”
This commentary echoes a broader sentiment shared across the longevity field. The aging demographic, coupled with the prevalence of chronic diseases, is straining healthcare systems worldwide, reinforcing the urgent need for preventative approaches. As life expectancy increases, policymakers, clinicians and researchers are keenly aware of the potential for therapeutic and lifestyle interventions to mitigate age-related conditions and enhance overall quality of life. However, much of the research to date stems from animal studies, and many in the industry are calling for further relevant evidence to support human applications. In this environment, the IIOL’s commitment to scientific rigor is both apposite and necessary, promising a structured pathway for translating emerging research into safe, effective clinical practice.
Global standards and ethical conduct
In its expanded role, the IIOL aims to support the establishment of industry standards that distinguish reputable providers and ensure high-quality care. “The longevity sector is growing exponentially in the last couple of years, with an increasing number of new actors entering the field especially in the area of longevity clinics,” explains Joanna Bensz. “It is important – as in any other mature sector – to establish industry standards and best practice, as well as to enhance collaboration between existing organizations.
“Our aim is to become the main professional platform to support development of the sector, with a focus on longevity clinics as well as professional suppliers of services and products.”
By working closely with the most reputable longevity clinics worldwide, the IIOL is committed to creating gold standards that enhance credibility and ethical conduct. Member clinics, by adhering to these guidelines, can improve their market differentiation and gain consumer trust, reinforcing a commitment to safe, evidence-based care. Additionally, the institute will offer training programs for practitioners to enhance their knowledge and skills, ultimately fostering a network of professionals aligned in their dedication to best practices.
Now and next
The IIOL’s plans for the coming months reflect its proactive approach. On 2nd November, the institute will present its comprehensive strategy at the Biomarkers of Aging Consortium event in Boston, followed by a second engagement at the Roundtable of Longevity Clinics at the Buck Institute for Research on Aging on 6th & 7th December. These events will offer platforms for further dialogue on the practical challenges and opportunities in longevity science, bringing together thought leaders from across the field.
According to Eric Verdin, the institute’s work is set to play a crucial role in shaping the future of longevity clinics. “This new not-for-profit initiative will be key in aligning all involved in the longevity clinical space to ensure that we deliver the best possible care to patients,” he said. “This is an important step both for patients’ safety and health and for the reputation of this growing field of clinical care. The establishment of this initiative and its future work represents a key landmark as we develop an ambitious program to change medicine to a more proactive stance focused on true preventative medicine.”
By addressing the challenges posed by a rapidly evolving field, the IIOL is seeking to build a cohesive framework that aligns with the needs of consumers, healthcare providers and policymakers alike. The institute’s commitment to advancing longevity science through ethical practices, rigorous standards and collaborative innovation is one we welcome, and we look forward to reporting on its successes improving a field that is both dynamic and complex.
